Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 54,948 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: lomustine, temozolomide; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Adult Ovarian Granulosa Cell Tumor
Interventions: Biospecimen Collection, Chest Radiography, Computed Tomography, Darolutamide, Exemestane, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more

Conditions: Iron Deficiency, Fibromyalgia
Interventions: Injectafer, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
Interventions: SPECT/CT perfusion imaging, PET/CT perfusion imaging; Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gastrointestinal Diseases
Interventions: Observational; Other
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Oxidative Stress, Inflammation, Endothelial Dysfunction
Interventions: Coenzyme Q10, Placebo; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: AZD6765, Placebo to AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematologic Neoplasms
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more

Conditions: Cancer
Interventions: Aspiration Thrombectomy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Mucositis
Interventions: OM Pain App, Accelerometer; Device
Lead sponsor: Stuart Wong; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Distress, Cancer, Chemotherapy Effect
Interventions: Mindfulness meditation program (administered via mobile app), Progressive muscle relaxation (via mobile app); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Lymphoma
Interventions: bortezomib; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma
Interventions: Drug: Carfilzomib, Vorinostat; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Rochester, New York • Richmond, Virginia

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Laparoscopic Greater Curvature Plication; Procedure
Lead sponsor: Singh, Kuldeep, M.D., P.A.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19 Vaccine, Cancer
Interventions: COVID-19 Vaccine; Biological
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy; Biological · Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina

Conditions: Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions: TPI 287 Injection; Drug
Lead sponsor: Cortice Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Acute Myeloid Leukemia
Interventions: G-CSF, Cytarabine, Fludarabine, Donor Natural Killer (NK) cells, ALT-801; Drug · Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 2 Years to 59 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oncology
Interventions: Results of the brief geriatric assessment, No results of brief geriatric assessments; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia
Interventions: Cyclophosphamide, Methotrexate, Prednisone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 68
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 48 more

Conditions: Ovarian Cancer
Interventions: Shared Medical Decision Tool, Engaging Patients in Decision Making, Literacy Spanish Language; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV/AIDS, Adherence, Medication, Drug Use
Interventions: Text Messaging, Peer Navigation; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Episodic Migraine
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more

Search by objective public record fields.

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

An Observational Study of Patients With Chronic Gastrointestinal Disease

CoQ10 Biomarker Trial

This is a Study to Determine the Antidepressant Effects of AZD6765

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)

Smartphone Pain App for Assessing Oral Mucositis Pain in Patients

POEM (Practice Of Embracing Each Moment) STUDY

Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Resolution of Comorbidities, Safety and Efficacy of Greater Curvature Plication in Obese Patients.

Host Immune Response to Novel RNA COVID-19 Vaccination

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Geriatric Assessment Reporting in Real Time (GARRT) in Non-electively Hospitalized Older Cancer Patients

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine